Summary Expression of pS2, an oestrogen-regulated gene, has been associated with a good short-term prognosis and response to endocrine therapy. The aim of this study was to determine whether expression of mRNA for the pS2 gene in breast cancer could contribute useful information on disease behaviour and survival at medium-term follow-up. Northern blotting was used to detect pS2 messenger ribonucleic acid (mRNA) in the primary tumour tissue from each of 90 patients with breast cancer. Axillary node status was established by sampling or clearance, oestrogen receptor concentration by enzyme immunosorbant assay and follow-up was continued for at least 6 years or until death. At 83 months mean follow-up, 29 of 90 (32%) patients had recurrent disease and, of these, 18 (20%) had died from breast cancer. pS2 mRNA expression, present in 26 of 90 (29%) cancers, was associated with freedom from disease recurrence (P = 0.026) and was significantly associated with survival at a minimum of 6 years follow-up (P < 0.001). Pathological node status and tumour size were also significantly associated with disease recurrence (P < 0.001 and P = 0.002 respectively) and inversely with survival (P < 0.001 and P < 0.001 respectively). After multiple Cox regression analysis, pS2 expression was still a significant predictor of recurrence (but not survival) after adjusting for node status and tumour size; oestrogen receptor was an independent predictor of survival. The combination of node status and pS2 expression discriminated patients with particularly good prognosis (node negative, pS2 positive: no mortality at 6 years) or poor prognosis (node positive, pS2 negative; 41% mortality at 6 years). Evaluation of pS2 expression in breast cancer at diagnosis may provide additional useful prognostic information to conventional staging.
The detection of pS2 expression in response to an oestrogenic stimulus in breast cancer cells (Masiakowski et al, 1982) -an effect that can be antagonized by tamoxifen -led to speculation that pS2 could be an oestrogen-regulated gene of clinical importance. The pS2 gene (also known as BCEI, pNR-2, Md2) encodes a 600-base mRNA (Masiakowski et al, 1982) , which is translated to a cysteine-rich protein with structural similarities to insulin-like growth factors I and II (Rio et al, 1987; Stack et al, 1988) . The clinical interest in pS2 is the result of an association with oestrogen receptor expression and with other conventional markers of good prognosis (Rio et al, 1987; Stack et al, 1988; Schwartz et al, 1991; Predine et al, 1992; Thompson et al, 1993; Detre et al, 1994; Foekens et al, 1994; Speiser et al, 1994; Gibert et al, 1996; Tutschek et al, 1996) . pS2 expression is associated with good prognosis in female -but not in male -patients at short-term follow-up (Foekens et al, 1990; Schwartz et al, 1991; Predine et al, 1992; Gion et al, 1993; Kardas et al, 1993; Thompson et al, 1993; Foekens et al, 1994; Speiser et al, 1994) . Conversely, pS2-negative patients have a significantly shorter relapse-free survival (Gion et al, 1993; Foekens et al, 1994; Speiser et al, 1994; Schmidt et al, 1996) and overall survival (Gion et al, 1993; Speiser et al, 1994) . pS2 also predicts a subsequent response to hormone manipulation as first-line therapy and on disease relapse (Henry et al, 1988 (Henry et al, , 1990 (Henry et al, , 1991 Schwartz et al 1991; Soubeyran et al, 1996) . Thus, the detection of pS2 expression in breast cancers may define a subset of cancers with functional oestrogen receptors and hence patients with a good prognosis who are more likely to respond to endocrine manipulation.
The aim of this study was to determine whether pS2 gene mRNA expression could contribute useful information on disease behaviour and survival after a minimum of 6 years (medium term) follow-up.
PATIENTS AND METHODS
Ninety female patients with primary, previously untreated, histologically proven, invasive breast cancer (mean age 56 years, range 30-78 years) underwent surgery for breast cancer. The 2-year follow-up on a subgroup of these women forms part of a previous report (Thompson et al, 1993) . Patients with impalpable disease or small tumours (when insufficient material was available for study) were excluded from the study. Fifty-six women were postmenopausal.
The tumour size on the resected specimen was measured as less than 2 cm (pTl) in nine patients, 2-4.9 cm (pT2) in 51 patients or greater than 5 cm (pT3) in 30 patients. Pathological axillary node status (based on 2-25 nodes per patient) was determined by axillary node sampling or clearance, with 46 of 90 patients node positive and 44 node negative at the time of diagnosis. The histology of the tumours was invasive ductal cancer of no special type (80 cancers), lobular breast cancer (seven) or special type (three). The mRNA in the cancer (----), demonstrating a significant association between pS2 mRNA expression (P < 0.026) and freedom from disease recurrence minimum of 5 years, 11 CMF and two underwent surgical oophorectomy. Clinical and radiological follow-up (including annual mammography) were continued for at least 6 years or until death; follow-up ranged from 5 to 98 months with a mean followup of 83 months. Total RNA was extracted from snap-frozen tumour tissue using the lithium chloride-urea method, and pS2 expression was determined using the Northern blot technique, with a cDNA probe (Masaikowski et al, 1982) used to detect pS2 messenger ribonucleic acid (mRNA) and actin (Minty et al, 1981) as an internal control for RNA loading (Thompson et al, 1993) . Figure 4 ) and with shorter disease-free interval recurrence and death rates at 6 years. Cox proportional hazards (P < 0.001) ( Figure 5 ). Tumour size, measured by the pathologist regression and multiple Cox regression were used to test whether on the resected specimen, was also significantly associated with pS2 mRNA expression, node status, tumour size on pathology recurrence (P < 0.001) and survival (P = 0.003). (1998) 77(3), [492] [493] [494] [495] [496] PS2 is prognostic at 6 years in breast cancer 495
By multiple Cox regression (Table 1) , node status and tumour size both remained independently significant for both recurrence and survival; pS2 expression was still a significant predictor of recurrence after adjusting for both these variables, but was not a predictor for mortality. Oestrogen receptor status became independently predictive of mortality (but not disease recurrence) after adjusting for nodes and size. The combination of node status and pS2 expression (Table 2 ) defined patients with particularly good prognosis (node negative, pS2 positive; no mortality at 5 years) or poor prognosis (node positive, pS2 negative; 41% mortality at 5 years). When the cancer did not express pS2 mRNA, patients who were node positive were significantly more likely (P < 0.001) to develop disease recurrence than patients who were node negative.
DISCUSSION
This study examined pS2 mRNA expression in 90 breast cancers and related pS2 expression to clinical and pathological parameters and to disease behaviour at a minimum follow-up of 6 years.
pS2 expression was detected in 29% of the breast cancers studied, which is within the range (22-58%) for mRNA detection in breast cancer reported by others (Rio et al, 1987; Stack et al, 1988; Skilton et al, 1989; Henry et al, 1990; Zaretsky et al, 1990; Hahnel et al, 1991; Delvenne et al, 1992; Wysocki et al, 1994) and similar to the range of 27-68% of breast cancers that express pS2 protein (Foekens et al, 1990; Henry et al, 1991; Schwartz et al, 1991; Walker et al, 1995; Tutschek et al, 1996) . The more recent development of reverse transcription polymerase chain reaction (RT-PCR), which may be a more sensitive method to detect pS2, allows both the detection and quantification of pS2 mRNA expression (Carr et al, 1995) . It is unclear whether improved sensitivity would effect the prognostic value of pS2 mRNA.
pS2 expression was significantly related to oestrogen receptor protein expression as expected for an oestrogen-regulated protein (Rio et al, 1987; Stack et al, 1988; Skilton et al, 1989; Henry et al, 1991; Schwartz et al, 1991; Predine et al, 1992; Thompson et al, 1993; Detre et al, 1994; Foekens et al, 1994; Speiser et al, 1994; Stonelake et al, 1994; Walker et al, 1995; Gibert et al, 1996; Tutschek et al, 1996) and we have confirmed the observations of others that pS2 expression (whether measured as mRNA or protein) is not significantly associated with tumour size or node status (Foekens et al, 1990; Schwartz et al, 1991; Delvenne et al, 1992; Gion et al, 1993) .
We have demonstrated that, at medium-term (6 year minimum, mean 83 months) follow-up, pS2 expression remains associated with good prognosis (Foekens et al, 1990; Schwartz et al, 1991; Predine et al, 1992; Thompson et al, 1993; Gion et al, 1993; Foekens et al, 1994; Speiser et al, 1994; Schmidt et al, 1996) in contrast to one other study of pS2 mRNA with a shorter follow-up (Wysocki et al, 1994) . Although our study, like that of Speiser et al (1994) , failed to identify pS2 as an independent prognostic factor for survival (which had been suggested by Gion et al, 1993; Foekens et al, 1994) , oestrogen receptor protein was associated with survival after adjusting for node status and tumour size. As expected, axillary node status (based on the pathological examination of surgically resected axillary lymph nodes) and tumour size were significantly associated with disease recurrence and survival both on univariate analysis and multivariate analysis.
The most important clinical implication of this study is the confirmation that pS2 expression has a discriminant effect for better prognosis in both axillary lymph node-positive (Foekens et al, 1990; Kausitz et al, 1994) and node-negative patients (Stonelake et al, 1994) . Furthermore, the data presented here suggest that a combination of axillary node status and pS2 expression measured at the time of diagnosis can define patients at high and low risk of death for medium-term follow-up. As pS2 expression is a good indicator of endocrine responsiveness both in the primary cancer and on relapse (Henry et al, 1988; Ramm et al, 1988; Skilton et al, 1989; Schwartz et al, 1991; Westley and May, 1991; Coradini et al, 1996; Soubeyran et al, 1996) , the detection of pS2 expression in the primary cancer, whether at the mRNA or the protein level, may be useful both as prognostic information and as a guide to therapeutic intervention. In this study, patients with tumours that were oestrogen receptor moderate/rich at diagnosis (therefore including the tumours that express pS2) were treated with tamoxifen. Thus, as changes in pS2 protein expression have been demonstrated during tamoxifen therapy (Wilsher et al, 1996) , it is possible that the apparent survival advantage at 5 years for the patients with pS2 mRNA detected in the tumour may be attributable to the effect of tamoxifen therapy mediated via pS2.
The usefulness of pS2 has been taken one step further in clinical practice; pS2 expression can be used to guide the likely response to tamoxifen therapy in patients with recurrent breast cancer (Foekens et al, 1994) . While pS2 expression by Northern blotting may not be suitable for routine pS2 analysis, pS2 measured by immunohistochemical staining (Wilson et al, 1994) or competitive reverse transcription polymerase chain reaction (Carr et al, 1995) on fine-needle aspirates of breast cancer has been used to select patients over the age of 70 years for tamoxifen therapy. pS2 expression in breast cancer tissue is useful in itself as a marker of probable hormonal response to endocrine manipulation. This study has demonstrated that pS2 mRNA expression also provides useful prognostic information in addition to that provided by axillary node status when oestrogen receptor expression may be of limited value. pS2 should now be considered for routine clinical measurement as a response indicator and prognostic marker alongside oestrogen receptor protein.
